{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:50:43Z","timestamp":1793922643090,"version":"4.8.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":4084,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2004,10]]},"DOI":"10.1111\/j.1523-1755.2004.00924.x","type":"journal-article","created":{"date-parts":[[2004,9,14]],"date-time":"2004-09-14T14:39:43Z","timestamp":1095172783000},"page":"1589-1595","source":"Crossref","is-referenced-by-count":246,"title":["Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta"],"prefix":"10.1016","volume":"66","author":[{"given":"Gabor E.","family":"Linthorst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla E.M.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma E.","family":"Donker-Koopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"Strijland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes M.F.G.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1523-1755.2004.00924.x_bb0010","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1056\/NEJMoa011931","article-title":"Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin","volume":"346","author":"Casadevall","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2004.00924.x_bb0015","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM199302183280701","article-title":"Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group","volume":"328","author":"Lusher","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2004.00924.x_bb0020","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2014Macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2004.00924.x_bb0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human \u03b1-galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2004.00924.x_bb0030","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: A randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1111\/j.1523-1755.2004.00924.x_bb0035","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(00)02533-2","article-title":"Recombinant human alpha-glucosidase from rabbit milk in Pompe patients","volume":"356","author":"VAN DEN HOUT","year":"2000","journal-title":"Lancet"},{"key":"10.1111\/j.1523-1755.2004.00924.x_bb0040","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","article-title":"Enzyme-replacement therapy in mucopolysaccharidosis I","volume":"344","author":"Kakkis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2004.00924.x_bb0045","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3733","article-title":"\u03b1-galactosidase A deficiency: Fabry disease,","volume":"Vol. 3","author":"Desnick","year":"2001"},{"key":"10.1111\/j.1523-1755.2004.00924.x_bb0050","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2004.00924.x_bb0055","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: Baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1111\/j.1523-1755.2004.00924.x_bb0060","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1517\/13543784.11.6.851","article-title":"Agalsidase alfa\u2014A preparation for enzyme replacement therapy in Anderson-Fabry disease","volume":"11","author":"Beck","year":"2002","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1111\/j.1523-1755.2004.00924.x_bb0065","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0140-6736(01)05816-0","article-title":"Enzyme-replacement therapy for Anderson-Fabry disease","volume":"358","author":"Pastores","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/j.1523-1755.2004.00924.x_bb0070","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0009-8981(81)90384-3","article-title":"Differential assay for lysosomal \u03b1-galactosidases in human tissues and its application to Fabry's disease","volume":"112","author":"Mayes","year":"1981","journal-title":"Clin Chim Acta"},{"key":"10.1111\/j.1523-1755.2004.00924.x_bb0075","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0021-9258(18)64849-5","article-title":"A simple method for the isolation and purification of total lipids from animal tissues","volume":"226","author":"Folch","year":"1957","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1523-1755.2004.00924.x_bb0080","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1182\/blood.V93.6.2081.406k07_2081_2088","article-title":"Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: Induction of humoral tolerance in seroconverted patients after repeat administration","volume":"93","author":"Rosenberg","year":"1999","journal-title":"Blood"},{"key":"10.1111\/j.1523-1755.2004.00924.x_bb0085","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1542\/peds.100.6.e11","article-title":"Management of neutralizing antibody to ceredase in a patient with type 3 Gaucher disease","volume":"100","author":"Brady","year":"1997","journal-title":"Pediatrics"},{"key":"10.1111\/j.1523-1755.2004.00924.x_bb0090","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.molmed.2003.08.004","article-title":"Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder","volume":"9","author":"Brooks","year":"2003","journal-title":"Trends Mol Med"},{"key":"10.1111\/j.1523-1755.2004.00924.x_bb0095","unstructured":"Food and Drug Administration: FDA briefing document Fabrazyme: 2002http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/briefing\/3917B1_03_FDA%20backgrounder.pdf"},{"key":"10.1111\/j.1523-1755.2004.00924.x_bb0100","unstructured":"Food and Drug Administration: FDA briefing report Replagal: 2002http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/briefing\/3917B2_02_FDA-backgrounder.pdf"},{"key":"10.1111\/j.1523-1755.2004.00924.x_bb0105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/345309","article-title":"Recombinant enzyme therapy for Fabry disease. Absence of editing of human \u03b1-galactosidase A mRNA","volume":"72","author":"Blom","year":"2003","journal-title":"Am J Hum Genet"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815502299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815502299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T13:41:35Z","timestamp":1624628495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815502299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["S0085253815502299"],"URL":"https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00924.x","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2004,10]]}}}